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Abstract
Background: Use of anti-hyperlipidemic medications compromises genetic analysis because of
altered lipid profiles. We propose an empirical method to adjust lipid levels for medication effects
so that the adjusted lipid values substitute the unmedicated lipid values in the genetic analysis.
Results: Published clinical trials were reviewed for HMG-CoA reductase inhibitors and fibric acid
derivatives as mono-drug therapy. HMG-CoA reductase inhibitors showed similar effects in African
Americans (AA) and non-African Americans (non-AA) for lowering total cholesterol (TC, -50.7
mg/dl), LDL cholesterol (LDL-C, -48.1 mg/dl), and triglycerides (TG, -19.7 mg/dl). Their effect on
increasing HDL cholesterol (HDL-C) in AA (+0.4 mg/dl) was lower than in Non-AA (+2.3 mg/dl).
The effects of fibric acid derivatives were estimated as -46.1 mg/dl for TC, -40.1 mg/dl for LDL-C,
and +5.9 mg/dl for HDL-C in non-AA. The corresponding effects in AA were less extreme (-20.1
mg/dl, -11.4 mg/dl, and +3.1 mg/dl). Similar effect for TG (59.0 mg/dl) was shown in AA and non-
AA. The above estimated effects were applied to a multipoint variance components linkage analysis
on the lipid levels in 2,403 Whites and 2,214 AA in the HyperGEN study. The familial effects did
vary depending on whether the lipids were adjusted for medication use. For example, the
heritabilities increased after medication adjustment for TC and LDL-C, but did not change
significantly for HDL-C and TG.
Conclusion:  Ethnicity-specific medication adjustments using our empirical method can be
employed in epidemiological and genetic analysis of lipids.
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Background
There is extensive epidemiological evidence showing that
a dyslipidemic profile, characterized by elevated plasma
levels of total cholesterol (TC), triglycerides (TG) and LDL
cholesterol (LDL-C), and reduced levels of HDL choles-
terol (HDL-C), is strongly associated with an increased
risk of atherosclerosis and coronary heart disease [1].
Genetic contributions to plasma lipid levels also have
been documented, with the magnitude as assessed by her-
itability being quite variable (26% to 83%) [2-4]. Simi-
larly, genome scans from different populations have
reported a variety of quantitative trait loci (QTLs) related
to lipid profiles [5-13].
However, it is known that use of anti-hyperlipidemic
medications by participants in such family studies distorts
their blood lipid levels. Consequently, investigators may
exclude subjects on medications during recruitment, or
remove them at the time of the genetic analyses. Not only
do such exclusions results in a smaller sample size, they
also may discard the participants who are most likely to
carry causative variants of dyslipidemia. To increase the
power of the analysis by including these potentially
informative subjects, some studies were designed to inter-
rupt lipid lowering medication for specific time intervals
before the blood samples were taken. Other methods that
have been implemented are to adjust the lipid levels for
medication by using medications as covariates in a linear
regression model. This method tends to minimize the dif-
ferences in lipid levels between medicated and unmedi-
cated groups, but not necessarily adjust lipid levels toward
their original values. To our knowledge, only one study
has performed a genome-wide scan for LDL-C after
increasing the measured levels by 25% for medicated sub-
jects [13]. The lod score for their highest peak increased
from 3.27, observed when analyzing 1977 white subjects
not on lipid lowering medications, to 3.72 after including
350 medicated subjects.
The aim of the present study is to recover or impute the
original unmedicated lipid levels using an empirical
approach. The measured (biased) lipid values of individ-
uals on lipid-lowering drugs are "adjusted" by increasing
(or decreasing) the measured value by the same amount
that clinical trials studies report decreases (or increases)
for a given class of drugs using ethnic-specific data. That is,
the approach statistically infers or projects what the origi-
nal lipid value would have been prior to medication treat-
ment. The impact of the medication adjustments will be
evaluated by computing heritabilities and by conducting
genome-wide linkage analyses in three samples: by
excluding medicated subjects; by including medicated
subjects after adjusting lipid values for medication use;
and by including medicated subjects without any medica-
tion adjustment. We hypothesize that imputing the origi-
nal lipid measurement by adjusting for medication effects
can provide more precise estimates of the medication-free
values of the phenotypes, with an expected increase in
power to detect genes involved in the lipid metabolism.
Methods
Subject description
The Hypertension Genetic Epidemiology Network
(HyperGEN) study is part of the National Heart, Lung and
Blood Institute (NHLBI) Family Blood Pressure Program.
The design and methods have been described in detail
elsewhere [14]. In the present report 2,403 White and
2,214 African American participants represent 1,924 pairs
of White hypertensive siblings in 1,242 nuclear families
and 1,889 pairs of African American hypertensive siblings
in 1,801 nuclear families. Among all participants with
measured serum lipid levels, 402 subjects reported that
they were taking medications to lower blood lipid levels.
This included 385 subjects taking one medication, 16 sub-
jects on combination drug therapy of two medications,
and 1 subject reporting the use of three drugs. IRB approv-
als were obtained for all participating centers, and all par-
ticipants gave their written informed consent.
Measurement of Lipids and Other Phenotypes
All blood assays on samples were performed at the Central
Biochemistry Laboratory at the University of Minnesota.
TG levels were colorimetrically determined by using a per-
oxidase-coupled method on a centrifugal analyzer [15].
TC was measured by using a commercial cholesterol oxi-
dase method [16]. LDL-C was estimated by the Friedewald
equation [17], or by ultracentrifugation for subjects with
TG above 400 mg/dl [18]. HDL-C was quantified by
COBAS FARA (Roche Diagnostic Systems) after precipita-
tion of the other lipoprotein fractions by dextran sulfate
[19].
Anthropometric measurements were collected with sub-
jects wearing lightweight suits. Body mass index (BMI)
was subsequently calculated as weight in kilograms
divided by height in meters squared. Waist circumference
was measured to the nearest centimeter at the level of the
umbilicus, and hip circumference was measured at the
level of the maximal circumference of the gluteus. All
other measurements were collected using a common,
standardized protocol administered by trained personnel.
Genotyping
The NHLBI Mammalian Genotyping Service (Marshfield,
Wisconsin) genotyped 391 markers at approximate 10-cM
intervals throughout the genome, with an average marker
heterozygosity of 76%. Detailed information on the gen-
otyping methods, instruments, and software used can be
found at the Marshfield Laboratory World Wide Web site
[20]. Quality control of the markers and the relationshipsBMC Genetics 2007, 8:60 http://www.biomedcentral.com/1471-2156/8/60
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in the pedigrees were carried out at the HyperGEN Data
Coordinating Center at Washington University in Saint
Louis, by using ASPEX [21], GRR [22], MAPMAKER/SIBS
[23], and PEDCHECK [24].
Adjustment for the effects of lipid-lowering medications
The majority of the participants in the HyperGEN study,
that were using anti-hyperlipidemic medications, were
prescribed two groups of medications: HMG-CoA reduct-
ase inhibitors (statins) and/or fibric acid derivatives
(Table 1). Therefore, we only focused on lipid-lowering
effects of these two groups of medications. Clinical trials
on the long-term effects of mono-drug therapy using these
anti-hyperlipidemic medications published in English
during 1989–2003 were searched online through
PubMed. The search terms used included lipids, efficacy,
mono-drug therapy, combination drug therapy, as well as
the names of medication classes. We excluded clinical tri-
als with duration of less than 8 weeks and those without
placebo control. Clinical trials for medication combina-
tions were also excluded unless they reported the data for
mono-drug therapy as well. Tables A1 and A2 in Appendix
A [see Additional File 1] summarize 32 clinical trials that
have investigated the effects of HMG-CoA inhibitors and
fibric acid derivatives as mono-drug therapy with com-
monly used dosages. A total of 19,384 participants, aged
18 to 80 years, with high blood lipid levels were pooled.
The clinical trials were double-blinded, randomized with
a course which varied from 8 to 280 weeks. Gemfibrozil
was the only fibric acid derivative used by the subjects in
the HyperGEN study; this medication was well repre-
sented in non-African Americans of the HyperGEN, but
only two African Americans used the drug (Table 1).
Therefore we reviewed only the clinical trials for the effects
of this medication in non-African Americans (see Addi-
tional File 1 Table A2).
The weighted (by sample size) average absolute change
for each lipid variables, which took into account placebo
effect, was calculated by medication groups based on eth-
nicity (African Americans vs. non-African Americans, and
vs. all ethnicities) (Table 2). Each phenotype of lipids
responded to different classes of drugs differently, and the
response also varied considerably by ethnicity. Non-Afri-
can Americans included mainly Whites and Hispanics.
The clinical trials for all ethnicities include more trials,
because some studies had samples that could not be cate-
gorized into either African Americans or non-African
Americans. HMG-CoA inhibitors showed similar reduc-
tions of TC, LDL-C and TG in African Americans and non-
African Americans. Thus, the following effect estimates, -
50.7 mg/dl, -48.1 mg/dl, and -19.7 mg/dl, were used for
all ethnicities in performing the adjustments, respectively.
However, non-African Americans appeared to be more
responsive than African Americans to HMG-CoA inhibi-
tors effecting HDL-C. The ethnicity specific average effects
(+2.3 mg/dl for non-African Americans and +0.4 mg/dl
for African Americans) were used to obtain the adjusted
HDL-C. Gemfibrozil appeared to be more effective as an
anti-hyperlipidemic agent for TC, LDL-C, and HDL-C in
non-African Americans than in populations with all
pooled ethnicities. For non-African Americans subjects
receiving Gemfibrozil, the measured levels of TC, LDL-C,
and HDL-C were adjusted by the following respective esti-
mates: -46.1 mg/dl, -40.1 mg/dl, and +5.9 mg/dl. Instead,
the measured lipid levels of two African Americans who
took Gemfibrozil were adjusted by the effect for all ethnic-
ities: -20.1 mg/dl for TC, -11.4 mg/dl for LDL-C, and + 3.1
mg/dl for HDL-C. Both African Americans and non-Afri-
can Americans were adjusted by -59.0 mg/dl for TG.
For the participants receiving mono-drug therapy of anti-
hyperlipidemics, the levels of TC, HDL-C, LDL-C, and TG
were adjusted with the effect estimates, where the sign (+/
-) indicates the increasing or lowering effect of a medica-
tion to a specific lipid component. When an individual
took a combination therapy of two drugs, the total effect
was estimated by selecting the medication with higher
effect on the lipids and conservatively adding up half
effect of the other medication. Unadjusted measurements
Table 1: Mechanisms of action for the major groups of antihyperlipidemic medications and their frequency of use by the subjects in 
HyperGEN
Medication group Mechanism Frequency of use
African 
Americans
Caucasians
Bile sequestrants A partial removal of bile acids from the enterohepatic circulation by preventing 
their absorption
11 2
Fibric acid derivatives Increasing fatty acid oxidation to decrease formation of VLDL (very low density 
lipoprotein) triglycerides
23 9
HMG CoA reductase inhibitors Inhibiting HMG CoA reductase, the rate-limiting step in cholesterol 
biosynthesis
101 264
Nicotinic acid derivatives Inhibiting lipoprotein synthesis and decrease the production of VLDL particles 1 0BMC Genetics 2007, 8:60 http://www.biomedcentral.com/1471-2156/8/60
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were used for 12 African Americans and 2 Whites who
took Bile Sequestrants or Nicotinic Acid Derivatives. The
third medication effect, which was presented for only one
participant, was not considered in our study.
Statistical Methods and Linkage Analysis
TG with and without medication adjustments were trans-
formed using natural logarithm to an approximate nor-
mal distribution. Each phenotype was then adjusted for
its mean and variance to remove the effects of age as well
as the effects of BMI, current smoking and drinking status,
the use of estrogen replacement therapy, diabetes status,
and the field center. Stepwise multiple regressions were
performed for the adjustment within each ethnicity and
sex group, retaining only the terms significant at the 5%
level. The adjusted variables were finally standardized to a
mean of 0 and a standard deviation (SD) of 1. Four to ten
outliers greater than 4 SD-s from the mean and at least 1
SD from the nearest data point were excluded within each
ethnic group for the lipid phenotypes.
Heritability (h2), defined as the percent of variance due to
additive familial effects, was estimated through the maxi-
mum-likelihood methods available in the software SEG-
PATH under the most parsimonious model using the
following equation [25]:
where rparent-offspring, rsibling, and rspouse denote the average
parent-offspring, the average sibling and the spouse corre-
lations, respectively. Two heritability estimates were
regarded as significantly different from each other if their
difference was greater than the sum of their standard
errors.
Genome-wide linkage analyses, both with and without
adjustments for medication effects, were performed for
each lipid phenotype by using variance component link-
age analysis as implemented in SEGPATH [26]. Linkage
analysis was carried out separately within ethnicity by
using ethnicity-specific marker allele frequencies derived
from the corresponding random sub-samples. Multipoint
IBD estimates were used in the linkage analysis.
Results
Table 3 presents the selected characteristics of participants
in the HyperGEN study by ethnic group and gender, and
the effects of adjustment for medication for each lipid
parameter. The average age was approximately 53 years in
Whites and 46 years in African Americans. African Ameri-
can females had higher levels of BMI than the other
groups. Alcohol consumption, smoking status, diabetes,
estrogen use, and field center also showed significant eth-
nic differences. When lipid levels in subjects on lipid-low-
ering medications were adjusted for medication effects,
there were observable elevations in the mean of TC and
LDL-C, but very slight changes in the mean of HDL-C and
in the log transformed TG.
The effects of medication adjustments on the heritabilities
of lipids are summarized in Table 4. Three groups of data
were analyzed: 1) Excluding medicated participants; 2) All
participants without any adjustment for medication
effects; 3) All participants with adjustment for medication
effects. Compared to the estimates without medication
adjustment, the heritabilities in Whites improved signifi-
h
rr r
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2 1
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=
++
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Table 2: Average effects estimated from published clinical trails by ethnicity for HMG-CoA reductase inhibitors and fibric acid 
derivatives
Medication Phenotype African Americans Non-African Americans * All
No. of pts 
pooled
Average effect 
(mg/dl) ± SE
No. of pts 
pooled
Average effect 
(mg/dl) ± SE
No. of pts
pooled
Average effect 
(mg/dl) ± SE
HMG-CoA 
reductase 
inhibitors
TC 572 -51.4 ± 11.2 10637 -52.1 ± 13.2 16811 -50.7 ± 13.9
LDL-C 572 -47.9 ± 7.2 10637 -49.9 ± 13.6 16811 -48.1 ± 13.9
HDL-C 572 +0.4 ± 1.7 10637 +2.3 ± 0.5 16811 +2.0 ± 0.8
TG 572 -18.8 ± 4.2 10637 -18.4 ± 3.7 16811 -19.7 ± 4.5
Fibric acid 
derivatives 
(Gemfibrozil)
TC -- 4 7 7 -46.1 ± 8.6 2573 -20.1 ± 15.3
LDL-C -- 4 7 7 -40.1 ± 7.0 2573 -11.4 ± 14.4
HDL-C -- 4 7 7 +5.9 ± 1.8 2573 +3.1 ± 1.6
TG - - 477 -57.1 ± 14.1 2573 -59.0 ± 10.4
* Non-African Americans mainly include Whites, Hispanic.
TC =Total Cholesterol; HDL-C = High Density Lipoprotein Cholesterol; LDL-C = Low Density Lipoprotein Cholesterol; TG = Triglycerides.BMC Genetics 2007, 8:60 http://www.biomedcentral.com/1471-2156/8/60
Page 5 of 9
(page number not for citation purposes)
Table 3: Characteristics of subjects by ethnicity and sex in the HyperGEN study
Variable Whites African Amercians
Males Females Males Females
Age, year (n) 52.9 ± 14.0 (1158) 53.7 ± 13.15 (1245) 45.25 ± 13.01 (814) 46.45 ± 13.32 (1400)
BMI, kg/m2 (n) 29.0 ± 4.7 (1156) 29.0 ± 6.84 (1242) 29.54 ± 6.32 (813) 33.38 ± 8.14 (1399)
Waist/hip, ratio (n) 1.0 ± 0.1 (1104) 0.9 ± 0.09 (1158) 0.93 ± 0.07 (800) 0.88 ± 0.08 (1366)
Drinking status, % yes (n) 42.71% (486/1138) 31.35% (380/1212) 47.64% (383/804) 21.08% (288/1366)
Smoking status, % yes (n) 9.50% (108/1137) 10.55% (128/1213) 37.81% (304/804) 22.62% (309/1366)
Diabetes, % yes (n) 10.02% (116/1158) 10.12% (126/1245) 14.00% (114/814) 18.94% (265/1399)
Estrogen, % yes (n) - 42.07% (509/1210) - 30.65% (418/1364)
Research center, % (n)
North Carolina 7.08% (82/1158) 12.61% (157/1245) 22.11% (180/814) 27.86% (390/1400)
Minnesota 28.76% (333/1158) 27.23% (339/1245) - -
Massachusetts 27.20% (315/1158) 28.59% (356/1245) - -
Utah 36.87% (427/1158) 31.41% (391/1245) - -
Alabama 0.09% (1/1158) 0.16% (2/1245) 77.89% (634/814) 72.14% (1010/1400)
LDL-C, mg/dL (n) 118.26 ± 30.62 (1107) 117.26 ± 33.10(1217) 119.79 ± 37.63 (790) 117.95 ± 37.00 (1376)
LDL-C (adjusted), mg/dL (n) 125.03 ± 32.78 (1107) 122.19 ± 36.55 (1217) 121.74 ± 39.49 (790) 120.12 ± 38.52 (1376)
HDL-C, mg/dL (n) 43.05 ± 10.87 (1155) 55.04 ± 15.42 (1240) 49.15 ± 14.73 (805) 55.99 ± 15.17 (1382)
HDL-C (adjusted), mg/dL (n) 42.62 ± 10.92 (1155) 54.78 ± 15.54 (1240) 49.13 ± 14.75 (805) 55.98 ± 15.18 (1382)
TC, mg/dL (n) 193.22 ± 35.84 (1155) 201.23 ± 37.97 (1240) 192.23 ± 41.67 (807) 194.20 ± 40.86 (1382)
TC (adjusted), mg/dL (n) 200.40 ± 38.66 (1155) 206.52 ± 42.05 (1240) 194.32 ± 43.84 (807) 196.51 ± 42.64 (1382)
* TG, mg/dL (n) 4.94 ± 0.58 (1155) 4.85 ± 0.55 (1240) 4.59 ± 0.58 (807) 4.49 ± 0.51 (1382)
* TG (adjusted), mg/dL (n) 4.96 ± 0.58 (1155) 4.86 ± 0.56 (1240) 4.60 ± 0.58 (807) 4.50 ± 0.51 (1382)
BMI = Body Mass Index; TC = Total Cholesterol; HDL-C = High Density Lipoprotein Cholesterol; LDL-C = Low Density Lipoprotein Cholesterol; 
TG = Triglycerides.
Table 4: The effect of medication correction on heritability of lipids: the HyperGEN study
Phenotype Excluding medicated subjects Including medicated subjects
N Heritability SE N Unadjusted with 
medications
Adjusted with 
medications
Significance
Heritability SE Heritability SE
African
Americans
TC 2088 0.57 0.07 2184 0.49 0.06 0.59 0.06 *
HDL-C 2080 0.30 0.05 2177 0.28 0.05 0.29 0.05
LDL-C 2067 0.65 0.07 2162 0.55 0.06 0.69 0.07 *
TG 2088 0.50 0.05 2183 0.48 0.06 0.50 0.05
Whites
TC 2092 0.52 0.06 2391 0.36 0.04 0.51 0.05 *
HDL-C 2086 0.47 0.06 2385 0.50 0.05 0.48 0.05
LDL-C 2034 0.53 0.06 2319 0.37 0.04 0.47 0.05 *
TG 2104 0.44 0.06 2390 0.32 0.04 0.34 0.04
* The estimates of heritability are significantly different with and without medication adjustment.
BMI = Body Mass Index; TC = Total Cholesterol; HDL-C = High Density Lipoprotein Cholesterol; LDL-C = Low Density Lipoprotein Cholesterol; 
TG = Triglycerides.BMC Genetics 2007, 8:60 http://www.biomedcentral.com/1471-2156/8/60
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cantly by 20% and 25% for TC and LDL-C, respectively,
when medication adjustments were applied. In African
Americans this significant improvement was 36% for TC
and 27% for LDL-C. By contrast, the heritability estimates
after medication adjustments for HDL-C and TG stayed
similar in both races. The heritability estimates for the
adjusted lipid levels were similar to those when excluding
medicated participants, suggesting that the medication
adjustment may recover the phenotypic correlations
within pedigrees previously obscured by medication.
A lod score of 1.75 (P < 0.0023) was set a priori as the
threshold for promising linkages, which previously was
shown to reduce the risk of type II errors to one false pos-
itive per genome scan (based on the assumption of dis-
crete marker density with approximately 400 markers)
[27]. Accordingly, all promising lod scores from the
multipoint variance components linkage analysis for
three samples, are presented in Table 5. Genome scan
results of the four lipid traits for three groups of data are
depicted in Figures A1-4 [see Additional File 1 Appendix
A]. The strongest linkage signal (lod score = 3.08) was
obtained for TG in African Americans excluding medi-
cated subjects. This was localized at 131 cM from p-tel-
omere (pter) on chromosome 11 (near marker
AFM157XH6). The lod score dropped to 2.73 when med-
icated subjects were included without adjustment, and
dropped to 2.71 when data were adjusted for the use of
lipid-lowering medications. In contrast, the peak for TC
on chromosome 6 at the region 53.81 cM p-ter (near
marker GGAA15B08) increased in African Americans
from 2.18 to 2.66 after the medication adjustment.
Discussion
The purpose of this study was to propose and explore a
method to adjust blood lipid measurements for the effects
of anti-hyperlipidemic medications. To our knowledge,
our empirical approach to adjust medication effects on
lipids has not been applied before in the genetic epidemi-
ology studies, although examples of other complex traits
exist. Several approaches have been attempted to adjust
blood pressure for the use of antihypertensive medica-
tions. We reported a similar empirical method to adjust
blood pressure based on a summary of over 160 clinical
trials on effects of anti-hypertensive medication [28]. A
nonparametric algorithm by ranking (the adjusted) blood
pressure was implemented by Levy et al. in the Framing-
ham Heart Study [29]. Hunt et al. compared three meth-
ods, including the use of a threshold method assigning a
fixed blood pressure (140/90 mm Hg) for all medicated
Table 5: Genome scan results (lod score ≥ 1.75) for lipids with and without medication correction by ethnicity: the HyperGEN study
Excluding medicated Including medicated
Phenotype Chromosome cM (from p-ter) Marker No. of 
sibs
Lod 
score
No. of 
sibs
Lod score
Medication 
unadjusted
Medication 
adjusted
African 
Americans
TC 6 53.81 GGAA15B08 1803 2.03 1889 2.18 2.66
21 36.77 ATA27F01 2.58 2.02 2.15
22 4.06 AFM217XF4 1.95 1.82 2.04
HDL-C 9 75.88 GATA89A11 1797 1.44 1884 2.11 2.07
LDL-C 2 132.58 GATA27A12 1786 1.46 1871 1.62 1.79
67 3 . 1 3 G A T A 1 1 E 0 2 2.22 2.36 1.81
21 57.77 GATA70B08 1.73 1.93 1.77
22 4.06 AFM217XF4 1.50 1.80 1.83
TG 6 73.13 GATA11E02 1803 1.89 1888 2.18 2.06
94 4 . 2 8 G A T A 8 7 E 0 2 2.00 1.05 0.93
11 131.26 AFM157XH6 3.08 2.73 2.71
Whites
TC 5 172.13 GATA7H10 1682 0.98 1924 0.73 1.92
14 91.62 GATA30A03 0.58 2.07 0.44
HDL-C 1 274.53 GATA50F11 1678 1.92 1919 1.00 0.84
8 0.73 AFM143XD8 1.24 2.19 1.67
20 32.94 GATA81E09 1.72 1.02 1.76
LDL-C 9 88.92 GATA81C04 1682 1.80 1858 0.43 0.59
BMI = Body Mass Index; TC = Total Cholesterol; HDL-C = High Density Lipoprotein Cholesterol; LDL-C = Low Density Lipoprotein Cholesterol; 
TG = TriglyceridesBMC Genetics 2007, 8:60 http://www.biomedcentral.com/1471-2156/8/60
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participants, and a random assignment of systolic blood
pressure between 140–160, and a random assignment of
diastolic blood pressure between 90–100 mm Hg [30].
The investigators concluded that excluding medicated
measurements or the use of unadjusted blood pressure
both lowered lod score results as compared to adjusting
blood pressure measurements. Cui et al. examined the
adjustment effects by adding an arbitrary 10 mm Hg and
5 mm Hg to systolic and diastolic blood pressures respec-
tively, according to a publication on clinical trials [31,32].
The adjusted blood pressure resulted in an increase of
both genetic and shared environmental variance compo-
nents, while the unadjusted blood pressure for antihyper-
tensive treatments obscured the relationship among
phenotypes and genotypes.
The heritabilities of lipids, estimated in our study by
excluding all the participants who took lipid-lowering
medications, should be less biased heritabilities. How-
ever, by excluding subjects there is a smaller sample size
and some valuable genetic information may be lost, espe-
cially alleles of the subjects affected more by dyslipidemia.
Including medicated participants would introduce bias,
because of a confounding of the medication effects with
the lipid levels. That is, the measured lipid levels are arti-
ficial. This could cause a reduction in the genetic variance
component as was seen for TC and LDL-C when we used
the whole sample without performing medication adjust-
ments. Heritabilities for TC and LDL-C were significantly
improved after medication adjustments to the similar
level as those obtained when excluding the medicated
subjects. This indicates that the adjustment with our
empirical method recovered relationships among pheno-
types and genotypes obscured by the use of medications.
Therefore, our method can provide the benefit of a greater
power in genetic analysis by increasing the sample size as
well as the information content.
The lod score for the TC peak in African Americans, cen-
tered at 53.81 cM on chromosome 6, increased from 2.03
to 2.66 when the medication adjustments were applied.
This linkage signal is about 25 cM from a suggestive signal
which was reported in a bivariate analysis of TG and LDL-
C (LOD = 2.0) from 1,747 African American siblings in
the Hypertension Genetic Epidemiology Network study
[33]. Another study provided evidence of linkage (LOD =
2.14) at 102 cM on chromosome 6 for combined hyperli-
pidemia of TC and TG in 113 Caucasian families [5]. In
contrast, the peak with a lod score of 3.08 dropped
slightly to 2.71 when including those measures with med-
ication adjustments for TG in African Americans on chro-
mosome 11 at 131 cM from p-ter. This peak replicates a
suggestive signal (LOD = 1.93) detected in French Canadi-
ans [6], and 30 cM from the region (LOD = 3.34) that
have previously been identified in Turkish families [34].
We performed meta-analysis across African American and
Caucasian families but there was no improvement in the
LOD scores (results not shown).
Blood lipid levels are the result of a complex interaction
among genetic and various environmental factors. The
power of genome scans for detecting true signals is gener-
ally low with small-to-modest effect for complex traits like
blood lipids. In addition, lipid-lowering treatment repre-
sents a pharmacologically induced alteration – typically of
large magnitude – of the plasma lipid levels which further
reduces the power to detect the true signals. One of the
methods to overcome the confounding of medication
effects with the measured lipid levels is to adjust the meas-
ured blood lipids by trying to recover the untreated levels
as closely as possible. Although we noticed that the lod
scores of blood lipids went both ways before and after
medication adjustment in the present study, we expect lod
scores for the medication adjusted analysis to be closest to
their optimal (true) estimates. To evaluate our empirical
approach of adjusting the treated lipid phenotypes, the
heritability is a more appropriate parameter, since it
reflects the effect size in linkage analysis. The higher herit-
abilities for TC and LDL-C when medication adjustments
were made in the present study indicate an improvement
in effect size of the linkage analysis with this empirical
method. This is consistent with what is known about the
HMG-CoA reductase inhibitors. First, as shown in Table 1
most of the medicated participants in the HyperGEN
study took HMG-CoA reductase inhibitors and the effects
is strongest on LDL-C and TC as shown in Table 3. Second,
these inhibitors primarily target LDL-C (and by extension
TC). For example, Table 2 shows larger mean and variance
effects due to medication use for LDL-C and TC in the
clinical trials literature.
Although our study has accounted for all participants and
adjusted lipid measurements for aggregate medication
effects, nevertheless there are limitations in the present
study. The effects of anti-hyperlipidemics were estimated
as group means rather than as individual responses to the
medications, which are notoriously dose-dependent.
Instead of producing precise untreated phenotype meas-
urements, an adjustment with the average effects of med-
ications may further serve as a shift by a constant and
obscure the association between the phenotype and geno-
type. Also, we focused only on two groups of lipid-lower-
ing medications, i.e., the most commonly used by subjects
in the HyperGEN study. Under different circumstances an
overall weighted average effect of other groups of anti-
hyperlipidemic medications could be used. Another issue
is that the present study did not ascertain the effect of the
different patient groups which may influence antihyperli-
pidemic responses. Although dose-specific effects should
be estimated when the information is available, the dosesBMC Genetics 2007, 8:60 http://www.biomedcentral.com/1471-2156/8/60
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used in each of the source clinical trials were pooled to
estimate the general efficacy for each group of medica-
tions because we do not have all the desired data in the
HyperGEN study, such as dosage of anti-hyperlipidemics
used by subjects. Similarly, we had to assume that the
medicated subjects in the HyperGEN study had been pre-
scribed, and were adhering, to the most commonly rec-
ommended doses. However, various strategies have been
implemented to improve the compliance significantly
during the clinical trials. The efficacy estimated from clin-
ical trials is likely to overestimate the results observed in a
general population of hyperlipidemic individuals under
the treatment, such as in the HyperGEN study. Therefore,
applying those estimates of drug effects would tend to
over adjust the lipid values for studies using general pop-
ulations.
Conclusion
In conclusion, this study provides a summary of a large
number of clinical trials on the average effects of anti-
hyperlipidemic medications on the actual lipid pheno-
types, and an empirical method to adjust measured lipids
for such medication effects. An illustrative example of
how to apply this methodology is presented for the
HyperGEN data. The medication adjustments using this
method resulted in an improvement in the heritability
estimates for TC, LDL-C, and TG. Genome scans with the
imputed lipid measurements revealed some promising
regions, such as a QTL with a peak lod score 2.66 at 53.81
cM from p-ter on chromosome 6 for TC and a region with
lod score of 2.71 centered at 131 cM on chromosome 11
for TG in African Americans. The method described and
the medication-use adjustments derived from a large body
of clinical trials can be employed in other epidemiologic
and genetic studies to obtain more accurate estimates of
the lipid measurements as well to preserve the power of
the study.
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